Loading the session
Loading the session
Loading instrument
$73.00
+0.34%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $72.75 on 4 Nov 2026: 0.9% below the 52-week high of $73.44 (3 Nov 2026) and 83.2% above the low of $39.71 (2 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
1 month: +24.7% (SPY −1.6%, XLV +13.5%). 3 months: +28.3% (SPY −0.4%, XLV +15.5%). 1 year: +92.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: EXEL, SPY and XLV · as of 4 Nov 2026
27.3M shares were sold short at the 15 Oct 2026 settlement, 11.2% of the 244.0M shares outstanding; covering them would take 11.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 14-session relative strength index closed at 86.2 on 4 Nov 2026, its 12th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
2 Nov 2026 volume of 5.6M shares was 2.5× the average of the 30 sessions before it (2.2M), as the price rose 1.1%. SPY traded 1.2× its own average that session.
Daily volume against a 30-session baseline · as of 2 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
July 29, 2025
−16.78%May 14, 2025
+20.84%August 7, 2024
+13.09%